Skip to content

Effects of Vitamin D and Calcium Supplementation on Inflammatory Biomarkers and Adypocytokines in Diabetic Patients

Effects of Vitamin D and Calcium Supplementation on Inflammatory Biomarkers and Adypocytokines in Diabetic Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01662193
Enrollment
120
Registered
2012-08-10
Start date
2012-02-29
Completion date
Unknown
Last updated
2012-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutritional and Metabolic Disease

Keywords

Cholecalciferol, Calciol, vitamin D3, Diabetes Mellitus, Diabetes Mellitus Type 2, glucose metabolism disorders, ergocalciferol, calcium, adipicytokines, inflammatory biomarkers

Brief summary

The epidemic of type 2 diabetes is an enormous public health problem in all parts of the world, with 366 million cases by 2030. Chronic inflammation has been postulated to play a role in the pathogenesis of type 2 diabetes. High levels of adiponectin and inflammatory biomarkers are known as a new risk factor for diabetes. There is accumulating evidence suggesting that altered vitamin D and calcium homeostasis affect the development of type 2 diabetes, but it is still unclear whether that effects are through reducing the level of adipocytokines and inflammatory biomarkers or not. This study has been designed to evaluate the effects of vitamin D and calcium supplementations alone and in combination on inflammatory biomarkers and adypocytokines in type 2 diabetic patients. This study is a single masked, controlled randomized trial with period of 8 weeks. 120 diabetic patients who met the inclusion criteria will enroll in this study. Subjects will randomly assign in to four groups. Randomization will be achieved by permuted blocks with stratification by age, sex, BMI, type of diabetes and dose of medication. Group1 will receive 50000 IU of vitamin D3 per week plus calcium placebo, group2 will received 1000 mg of calcium carbonate per day plus vitamin D placebo, group 3 will receive 50000 IU of vitamin D3 plus 100 of mg calcium carbonate per day and group four will receive calcium and vitamin D placebos. Total cholesterol, HDL, LDL, serum triglyceride, serum glucose, serum insulin, HbA1C, leptin, adiponectin and inflammatory biomarkers such as TNF-alpha, IL-6 and high sensitivity C reactive protein (hs-CRP) will be determine by taking blood samples at the baseline and at the end of intervention. Systolic and diastolic blood pressure and anthropometric measurements (height, weight, hip and waist circumferences) will be measured at the baseline and after 8 weeks of intervention. 3 dietary records and 3 physical activity records will be taken at 2,4 and 6 week of intervention to make sure that all subjects maintain their usual diet and physical activity during intervention.

Interventions

DIETARY_SUPPLEMENTvitamin D3 supplement
DIETARY_SUPPLEMENTcalcium supplement
DIETARY_SUPPLEMENTvitamin D3 and calcium supplement
DIETARY_SUPPLEMENTplacebo

Sponsors

Isfahan University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* more than 30 years old * have no history of renal failure, cancer, liver diseases, thyroid diseases or any other inflammatory diseases * have no allergy * do not use any tobacco products * not using corticosteroids * not consuming any kinds of vitamin D or calcium supplement * have not more than 4 kilograms weight change during last 3 months

Exclusion criteria

* pregnancy * insulin dependent diabetes

Design outcomes

Primary

MeasureTime frameDescription
change in inflammatory biomarkers from baseline at 8 weeks8 weeksincluding:IL-6, TNF-alpha, hs-CRP
change in adipocytokines from baseline at 8 weeks8 weeksincluding: adiponectin and leptin

Secondary

MeasureTime frameDescription
change in weight (Kg) from baseline at 8 weeks8 weeks
change in lipid profile from baseline at 8 weeks8 weeksincluding: LDL, HDL, total cholesterol, TG
change in serum Glucose from baseline at 8 weeks8 weeks
change in height (Cms) from baseline at 8 weeks8 weeks
change in hip circumference (Cms) from baseline at 8 weeks8 weeks
change in waist circumference (Cms) from baseline at 8 weeks8 weeks
change in serum Insulin from baseline at 8 weeks8 weeks
change in HbA1C from baseline at 8 weeks8 weeks
change in blood pressure from baseline at 8 weeks8 weeks

Countries

Iran

Contacts

Primary Contactmarjan tabesh, MS
tabesh@hlth.mui.ac.ir00989131664159

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026